Title (en)

AGENTS INHIBITING TCTP PROTEIN FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA

Title (de)

TCTP-PROTEIN-INHIBITOREN ZUR BEHANDLUNG VON PROLIFERATIVEN KRANKHEITEN, INFEKTIONSKRANKHEITEN, ALLERGIEN, ENTZÜNDUNGEN UND/ODER ASTHMA

Title (fr)

AGENTS INHIBANT LA PROTEINE TCTP POUR LE TRAITEMENT DE MALADIES PROLIFERATIVES, DE MALADIES INFECTIEUSES, D'ALLERGIES, D'INFLAMMATIONS ET/OU DE L'ASTHME

Publication

EP 3687512 A1 20200805 (FR)

Application

EP 18792980 A 20181001

Priority

• FR 1759102 A 20170929
• FR 2018052410 W 20181001

Abstract (en)

[origin: WO2019063955A1] The present invention concerns the compounds of the following formula (I): (I) in which: - X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, - The X--Y bond and Y are absent if X represents an oxygen or sulfur atom, the X--Y bond and Y are present if X represents a nitrogen atom or a CH radical, - When it is present, Y represents - an R group if X represents a nitrogen atom, - a hydrogen atom or an –NR1R2 group if X represents a CH radical, - (Het)Ar is an aromatic ring chosen from the group constituted by the aryl and heteroaryl groups, -R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, an –NR12R13 group, an –SR14 group, an –OR14 group or a -CF3 group, - When Y represents an –NR1R2 group, the –NR1R2 and (Het)Ar groups are in cis configuration, or a pharmaceutically acceptable salt of same, for the use thereof in the treatment of proliferative diseases, infectious diseases, allergies, an inflammation and/or asthma.

IPC 8 full level

A61K 31/015 (2006.01); A61K 31/03 (2006.01); A61K 31/085 (2006.01); A61K 31/165 (2006.01); A61K 31/235 (2006.01); A61K 31/24 (2006.01); A61K 31/353 (2006.01); A61K 31/382 (2006.01); A61K 31/404 (2006.01); A61K 31/7036 (2006.01); A61K 31/706 (2006.01); A61P 33/06 (2006.01); A61P 35/02 (2006.01); C07C 69/76 (2006.01); C07C 211/38 (2006.01); C07C 233/10 (2006.01); C07D 209/08 (2006.01); C07D 311/20 (2006.01); C07D 335/06 (2006.01); C07H 13/08 (2006.01); C07H 15/203 (2006.01)

CPC (source: EP US)

A61K 31/015 (2013.01 - EP US); A61K 31/03 (2013.01 - EP US); A61K 31/085 (2013.01 - EP US); A61K 31/09 (2013.01 - US); A61K 31/11 (2013.01 - US); A61K 31/135 (2013.01 - US); A61K 31/165 (2013.01 - EP US); A61K 31/197 (2013.01 - US); A61K 31/235 (2013.01 - EP US); A61K 31/24 (2013.01 - EP US); A61K 31/352 (2013.01 - US); A61K 31/353 (2013.01 - EP); A61K 31/382 (2013.01 - EP US); A61K 31/404 (2013.01 - EP US); A61K 31/472 (2013.01 - US); A61K 31/7036 (2013.01 - EP); A61K 31/704 (2013.01 - US); A61K 31/706 (2013.01 - EP US); A61K 31/7068 (2013.01 - US); A61P 33/06 (2017.12 - EP); A61P 35/00 (2017.12 - US); A61P 35/02 (2017.12 - EP); C07C 13/48 (2013.01 - EP); C07C 25/22 (2013.01 - EP); C07C 43/21 (2013.01 - EP); C07C 43/285 (2013.01 - EP); C07C 43/29 (2013.01 - EP); C07C 47/546 (2013.01 - EP); C07C 69/76 (2013.01 - EP); C07C 211/38 (2013.01 - EP); C07C 211/42 (2013.01 - EP); C07C 233/04 (2013.01 - EP); C07C 233/10 (2013.01 - EP); C07C 233/14 (2013.01 - EP); C07C 233/52 (2013.01 - EP); C07C 323/41 (2013.01 - EP); C07D 209/08 (2013.01 - EP); C07D 311/58 (2013.01 - EP); C07D 335/06 (2013.01 - EP); C07H 13/08 (2013.01 - EP); C07H 15/203 (2013.01 - EP); C07C 2601/10 (2017.04 - EP); Y02A 50/30 (2017.12 - EP)

Citation (search report)

See references of WO 2019063955A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2019063955 A1 20190404; CA 3076794 A1 20190404; EP 3687512 A1 20200805; FR 3071726 A1 20190405; FR 3071726 B1 20200904; JP 2020536860 A 20201217; US 2020253996 A1 20200813

DOCDB simple family (application)

FR 2018052410 W 20181001; CA 3076794 A 20181001; EP 18792980 A 20181001; FR 1759102 A 20170929; JP 2020518511 A 20181001; US 201816651719 A 20181001